Abstract:Drug–drug interactions involving cytochrome P450 (CYP450s) are an important factor for evaluation of a new chemical entity (NCE) in drug development. To evaluate the potential inhibitory effects of a NCE on the pharmacokinetics of a cocktail of representative probes of CYP enzymes (midazolam for CYP3A4, tolbutamide for CYP2C9, omeprazole for CYP2C19 and dextromethorphan for CYP2D6) and the safety and tolerability of the NCE in the presence of probe substrates, a high throughput liquid chromatography/tandem mass spectrometry (LC–MS/MS) method was developed and validated for the simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma using tolbutamide-d9, midazolam-d4, (±)-omeprazole-d3, and dextromethorphan-d3 as the internal standards (ISs). Human plasma samples of 50μL were extracted by a simple protein-precipitation procedure and analyzed using a high performance liquid chromatography electrospray tandem mass spectrometer system. Reversed-phase HPLC separation was achieved with a Hypersil GOLD AQ column (50mm×4.6mm, 5μm). MS/MS detection was set at mass transitions of 271→172 m/z for tolbutamide, 346→198 m/z for omeprazole, 326→291 m/z for midazolam, 272→171 m/z for dextromethorphan, 280→172 m/z for tolbutamide-d9 (IS), 349→198 m/z for (±)-omeprazole-d3 (IS), 330→295 m/z for midazolam-d4 (IS), and 275→171 m/z for dextromethorphan-d3 (IS) in positive mode. The high throughput LC–MS/MS method was validated for accuracy, precision, sensitivity, stability, recovery, matrix effects, and calibration range. Acceptable intra-run and inter-run assay precision (<10%) and accuracy (<10%) were achieved over a linear range of 50–50,000ng/mL for tolbutamide, 1–1000ng/mL for omeprazole, 0.1–100ng/mL for midazolam and 0.05–50ng/mL for dextromethorphan in human plasma. Method robustness was demonstrated by the 100% pass rate of 24 incurred sample analysis runs and all of the 50 clinical study samples used for incurred sample reproducibility (ISR) test having met the acceptance criterion (%Diff within 20%). The overall ISR results for all compounds showed that over 95% of the samples had a %Diff of less than 10%. The method is simple, rapid and rugged, and has been applied successfully to sample analysis in support of a drug–drug interaction study.

A High-Throughput Inhibition Screening Of Major Human Cytochrome P450 Enzymes Using An In Vitro Cocktail And Liquid Chromatography-Tandem Mass Spectrometry

A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.

Rapid Determination of Six Metabolites from Multiple Cytochrome P450 Probe Substrates in Human Liver Microsome by Liquid Chromatography/Mass Spectrometry: Application to High-Throughput Inhibition Screening of Terpenoids

A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug–drug interaction evaluation

Rapid and Accurate Liquid Chromatography and Tandem Mass Spectrometry Method for the Simultaneous Quantification of Ten Metabolic Reactions Catalyzed by Hepatic Cytochrome P450 Enzymes.

Development and Full Validation of Six Inhibition Assays for Five Major Cytochrome P450 Enzymes in Human Liver Microsomes Using an Automated 96-Well Microplate Incubation Format and Lc-Ms/Ms Analysis

A Simple LC-MS/MS Method for the Simultaneous Quantification of Drug Metabolic Enzymes

High-throughput assay to simultaneously evaluate activation of CYP3A and the direct and time-dependent inhibition of CYP3A, CYP2C9, and CYP2D6 using liquid chromatography-tandem mass spectrometry

Investigation of the inhibition of eight major human cytochrome P450 isozymes by a probe substrate cocktail in vitro with emphasis on CYP2E1

Evaluation of the Effect of TM208 on the Activity of Five Cytochrome P450 Enzymes Using On-Line Solid-Phase Extraction HPLC–DAD: A Cocktail Approach

A simple LC-MS/MS method for the simultaneous quantification of drug metabolic enzymes.

Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential

Simultaneous Determination of Tolbutamide, Omeprazole, Midazolam and Dextromethorphan in Human Plasma by Lc-Ms/Ms-A High Throughput Approach to Evaluate Drug-Drug Interactions

Absolute Quantification of Cytochrome P450 and Uridinediphosphate Glucuronosyl Transferase Isoforms by Proteomics-based Approach

Determination the inhibitory potency of bencycloquidium bromide on rat liver cytochrome P450 by LC-MS/MS

Development of a high throughput cytochrome P450 ligand-binding assay

Establishment of in vitro methods for evaluation of induction and inhibition of human CYP450 enzymes by drugs

Rapid Determination of CYP2 C9 Activity by UPLC-MS/MS

Simultaneous quantitation of hydrochlorothiazide and metoprolol in human plasma by liquid chromatography-tandem mass spectrometry.

Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes

Quantifying Four-Probe Metabolites in A Single Uplc-Ms/Ms Run to Explore the Effects of Cooked Rhubarb on Cytochrome P450 Isozymes